Enterprise Value
5.50B
Cash
355.5M
Avg Qtr Burn
-148.7M
Short % of Float
12.88%
Insider Ownership
13.24%
Institutional Own.
96.02%
Qtr Updated
12/31/23
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Empaveli (systemic pegcetacoplan) (APL-2) Details Paroxysmal nocturnal hemoglobinuria | Approved Quarterly sales | |
SYFOVRE™(Intravitreal pegcetacoplan) Details Geographic atrophy, Age-related macular degeneration | Approved Quarterly sales | |
Systemic pegcetacoplan (APL-2) Details C3 Glomerulopathy, Immune complex membranoproliferative glomerulonephritis | Phase 3 Data readout | |
Systemic pegcetacoplan (APL-2) Details Hematopoietic stem cell transplantation thrombotic microangiopathies | Phase 2 Data readout | |
Systemic pegcetacoplan (APL-2) Details Immune complex membranoproliferative glomerulonephritis, C3 Glomerulopathy | Phase 2 Update | |
APL-3007 (small interfering RNA silencing C3) Details Autoimmune disease, Inflammatory disease | Phase 1 Data readout | |
Intravenous APL-9 Details ARDS (Acute respiratory distress syndrome), TMA (Thrombotic microangiopathies) | Failed Discontinued | |
Systemic pegcetacoplan (APL-2) Details Cold agglutinin disease | Failed Discontinued | |
Systemic pegcetacoplan (APL-2) Details Amyotrophic lateral sclerosis | Failed Discontinued |